Organization | bluebird bio

bluebird bio Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Cambridge MA United States (1992)

Organization Overview

First Clinical Trial

2013

NCT02151526

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

bluebird bio | bluebird bio, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

autologous cd34+ cell-enriched population that contains cells transduced with lenti-d lentiviral vector that encodes an abcd1 cdna (1 trial)

lenti-d drug product (1 trial)

lentiglobin bb305 (Zynteglo) (6 trials)

Drugs in Phase 2 Trials (3)

autologous bone marrow derived cd34+ hsc cells transduced with the lentiviral vector containing a short-hairpin rna targeting bcl11a (1 trial)

mgta-145 (1 trial)

plerixafor (mozobil) (2 trials)

Drugs in Phase 1 Trials (4)

autologous ebv-ctl transduced with vector sfg-cna12 (1 trial)

bb2121 (2 trials)

ciltacabtagene autoleucel (Carvykti) (1 trial)

sc-daric33 (1 trial)

Drugs in Other Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adrenoleukodystrophy (Phase 3)

Anemia, Sickle Cell (Phase 3)

beta-Thalassemia (Phase 3)

Lymphoproliferative Disorders (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Thalassemia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 16
# of Trial APIs: 11